Covidien (COV) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Join SI Premium – FREE
Covidien (NYSE: COV) reported Q4 EPS of $1.15, $0.13 better than the analyst estimate of $1.02. Revenue for the quarter came in at $2.73 billion versus the consensus estimate of $2.69 billion.
For earnings history and earnings-related data on Covidien (COV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Innospec (IOSP) Tops Q3 EPS by 2c
- Limbach Holdings (LMB) Tops Q3 EPS by 16c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
